Publication
A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
Charles X Wang, Guillaume Luxardi, Hidetoshi Mori, Emanual M Maverakis, Alexander A Merleev, Alina I Marusina, Alexander D Borowsky, Mamta Parikh, Jonathan W Riess, Ala Moshiri, Lyudmila Bazhenova, Matthew Gubens, Marianna Koczywas, Joseph D Butner, Jonathan Huang, Soo Kyoung Kim, Logan V Vick, Yaohui Sun, Robert J Canter, William J Murphy, Megan E Daly, Karen Kelly, Arta M Monjazeb
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) therapy, but only 25% of patients have durable responses. TG4010, a mucin 1 (MUC1) vaccine, has demonstrated activity in NSCLC. We conducted a multi-institutional study to determine the safety and activity of…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT02823990registry_reference1.00
Candidate 1
- cancerMalignant Lung Neoplasmdictionary0.60
Registered trialsNCT02823990
Curated evidence
Evidence citing this paper (0)
Data not yet available